Federal Register / Vol. 87, No. 66 / Wednesday, April 6, 2022 / Notices 19939 

posted on https://www.regulations.gov. 

Therefore, do not include any 

information in your comment or 

supporting materials that you consider 

confidential or inappropriate for public 

disclosure. If you include your name, 

contact information, or other 

information that identifies you in the 

body of your comments, that 

information will be on public display. 

CDC will review all submissions and 

may choose to redact, or withhold, 

submissions containing private or 

proprietary information such as Social 

Security numbers, medical information, 

inappropriate language, or duplicate/ 

near duplicate examples of a mass-mail 

campaign. CDC will carefully consider 

all comments submitted into the docket. 

Written Public Comment: The docket 

will be opened to receive written 

comments on April 6, 2022 through 

April 28, 2022. 

Oral Public Comment: This meeting 

will include time for members of the 

public to make an oral comment. Oral 

public comment will occur before any 

scheduled votes. Priority will be given 

to individuals who submit a request to 

make an oral public comment before the 

meeting according to the procedures 

below. 

Procedure for Oral Public Comment: 

All persons interested in making an oral 

public comment at the May 3, 2022, 

ACD meeting must submit a request by 

visiting https://www.cdc.gov/about/ 

advisory-committee-director/ no later 

than 11:59 p.m., EDT, April 22, 2022, 

according to the instructions provided. 

If the number of persons requesting to 

speak is greater than can be reasonably 

accommodated during the scheduled 

time, CDC will conduct a lottery to 

determine the speakers for the 

scheduled public comment session. 

CDC staff will notify individuals 

regarding their request to speak by email 

by April 26, 2022. To accommodate the 

significant interest in participation in 

the oral public comment session of ACD 

meetings, each speaker will be limited 

to 2 minutes, and each speaker may 

only speak once per meeting. 

The Director, Strategic Business 

Initiatives Unit, Office of the Chief 

Operating Officer, Centers for Disease 

Control and Prevention, has been 

delegated the authority to sign Federal 

Register notices pertaining to 

announcements of meetings and other 

committee management activities, for 

both the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Kalwant Smagh, 

Director, Strategic Business Initiatives Unit, 

Office of the Chief Operating Officer, Centers 

for Disease Control and Prevention. 

[FR Doc. 2022–07247 Filed 4–5–22; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended, and the Determination of 

the Director, Strategic Business 

Initiatives Unit, Office of the Chief 

Operating Officer, CDC, pursuant to 

Public Law 92–463. The grant 

applications and the discussions could 

disclose confidential trade secrets or 

commercial property such as patentable 

material, and personal information 

concerning individuals associated with 

the grant applications, the disclosure of 

which would constitute a clearly 

unwarranted invasion of personal 

privacy. 

Name of Committee: Disease, 

Disability, and Injury Prevention and 

Control Special Emphasis Panel (SEP)— 

RFA–OH–22–002, Panel B and Panel D, 

NIOSH Centers for Agricultural Safety 

and Health. 

Dates and Times: May 9–10, 2022, 

Panel B, 11:00 a.m.–6:00 p.m., EDT; and 

May 11–12, 2022, Panel D, 11:00 a.m.– 

6:00 p.m., EDT. 

Place: Video-Assisted Meeting. 

Agenda: To review and evaluate grant 

applications. 

For Further Information Contact: Dan 

Hartley, Ed.D., Scientific Review 

Officer, Office of Extramural Programs, 

National Institute for Occupational 

Safety and Health, CDC, 1095 

Willowdale Road, Morgantown, West 

Virginia 26505, Telephone: (304) 285– 

5812; Email: DHartley@cdc.gov. 

The Director, Strategic Business 

Initiatives Unit, Office of the Chief 

Operating Officer, Centers for Disease 

Control and Prevention, has been 

delegated the authority to sign Federal 

Register notices pertaining to 

announcements of meetings and other 

committee management activities, for 

both the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Kalwant Smagh, 

Director, Strategic Business Initiatives Unit, 

Office of the Chief Operating Officer, Centers 

for Disease Control and Prevention. 

[FR Doc. 2022–07245 Filed 4–5–22; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Clinical Laboratory Improvement 

Advisory Committee (CLIAC); Notice of 

Charter Renewal 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice of charter renewal. 

SUMMARY: This gives notice under the 

Federal Advisory Committee Act of 

October 6, 1972, that the Clinical 

Laboratory Improvement Advisory 

Committee (CLIAC), Centers for Disease 

Control and Prevention, Department of 

Health and Human Services, has been 

renewed for a 2-year period through 

February 19, 2024. 

FOR FURTHER INFORMATION CONTACT: 

Reynolds M. Salerno, Ph.D., Designated 

Federal Officer, Clinical Laboratory 

Improvement Advisory Committee 

(CLIAC), Centers for Disease Control 

and Prevention, 1600 Clifton Road NE, 

Mailstop V24–3, Atlanta, Georgia 

30329–4027, Telephone: (404) 498– 

6516; Email: RSalerno@cdc.gov. 

The Director, Strategic Business 

Initiatives Unit, Office of the Chief 

Operating Officer, Centers for Disease 

Control and Prevention, has been 

delegated the authority to sign Federal 

Register notices pertaining to 

announcements of meetings and other 

committee management activities, for 

both the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Kalwant Smagh, 

Director, Strategic Business Initiatives Unit, 

Office of the Chief Operating Officer, Centers 

for Disease Control and Prevention. 

[FR Doc. 2022–07240 Filed 4–5–22; 8:45 am] 

BILLING CODE 4163–18–P 


lotter on DSK11XQN23PROD with NOTICES1